A drug discovery engine
for genetic diseases
A drug
discovery
engine for
genetic
diseases

Treating individuals with rare diseases
to uncover solutions for millions

From personalized medicine for individuals to precision medicine for populations
QR genetics develop a powerful AI-supported drug discovery engine
that identifies potential therapies for common genetic diseases,
by uncovering new treatments for individual patients with similar rare disease mutations

From personalized medicine for individuals to precision medicine for populations QR genetics develop a powerful AI-supported drug discovery engine
that identifies potential therapies for
common genetic diseases,
by uncovering new treatments for individual patients with similar rare disease mutations

Our Unique Discovery Process

01
Patient
data
Disease
data
Proprietary
database
Proprietary
Algorithms
Disease
Modeling
Protein
Modeling
Target
Identification
Drug
Discovery
02
Rapid clinical validation through preclinical tests, & in-human trials
03
Proprietary
Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders
04
Pre-clinical and Clinical trials in partnership with pharma or academia

Our discovery edge

De-risking the clinical stages of drug development through in-human validation
Discovery time reduction from 3 years to 3 months
Parallel exploration of multiple diseases and drug candidates

Autism Case Study

Pre-treatment

7 years old
Was diagnosed with Autism spectrum disorder-level 3, caused by a point mutation that impacted his growth and development.

POST-treatment

8 years old
After 1 year of treatment with a repurposed drug.
Knows how to read. Can communicate with his surroundings, with friends and with family.

Drug Indication
Expansion

Therapy was found beneficial for
> 100,000
autism patients with a specific mutated protein

Pipeline

Drug
name
indication
type
indication
name
Pre-clinical
IND enabling
RESULTS
Clinical trial
by academic
or pharma
partner
QR-100
Rare
Common
Neurodevelopmental disorder (NDPLH)
Autism Spectrum Disorder (ASD)
QR-295
Rare
Common
Central core disease of muscle (CCD)
Myopathy
QR-172
Rare
Common
Common
Common
Common
Common
Common
Common
Smooth Muscle Disease
Cardiomyopathy
Abdominal and aortic Aneurysm
Visceral myopathy
Deafness
Dystonia
Nemaline Myopathy
Basal cell carcinoma

Management team

Dr. Shane Wald Altman. Ph.D.

Co-Founder & CEO

Prof. Miguel Weil, Ph.D.

Co-Founder & Scientific advisor

Dan Lavi

Co-Founder, Entrepreneur
& Business Management

Dr. Noa Bielopolski, Ph.D.

Director of Science

Ido Gonen

Board Member and
Business development
consultant

Dr. Dan Goldstaub

Board member
and Pharma consultant

Collaborators

Prof. Arnold Levine

Board Member and
Cancer research specialist

Contact us

A. Rokach Blvd 97, Tel Aviv-Yafo